183 related articles for article (PubMed ID: 15719708)
41. Cox-2 inhibitors: still no decisive action.
Prescrire Int; 2005 Jun; 14(77):102. PubMed ID: 15981408
[TBL] [Abstract][Full Text] [Related]
42. The interrelationship between preoperative anemia and N-terminal pro-B-type natriuretic peptide: the effect on predicting postoperative cardiac outcome in vascular surgery patients.
Goei D; Flu WJ; Hoeks SE; Galal W; Dunkelgrun M; Boersma E; Kuijper R; van Kuijk JP; Winkel TA; Schouten O; Bax JJ; Poldermans D
Anesth Analg; 2009 Nov; 109(5):1403-8. PubMed ID: 19843778
[TBL] [Abstract][Full Text] [Related]
43. [Changes of serum N-terminal pro-brain natriuretic peptide levels in patients with cardiovascular diseases and its clinical significance].
Yang CL; Qiu YR; Zhou F; Feng PF
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):866-9. PubMed ID: 18504223
[TBL] [Abstract][Full Text] [Related]
44. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease.
Rothenbacher D; Koenig W; Brenner H
Arch Intern Med; 2006 Dec 11-25; 166(22):2455-60. PubMed ID: 17159010
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
Ruff CT; Morrow DA; Jarolim P; Ren F; Contant CF; Kaur A; Curtis SP; Laine L; Cannon CP; Brune K
J Rheumatol; 2011 Jun; 38(6):1071-8. PubMed ID: 21459935
[TBL] [Abstract][Full Text] [Related]
46. Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure.
Omland T
Crit Care Med; 2008 Jan; 36(1 Suppl):S17-27. PubMed ID: 18158473
[TBL] [Abstract][Full Text] [Related]
47. N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART.
Berg T; Zdunek D; Stalke J; Dupke S; Baumgarten A; Carganico A; Hess G
Eur J Med Res; 2007 Apr; 12(4):152-60. PubMed ID: 17509959
[TBL] [Abstract][Full Text] [Related]
48. N-terminal pro-B-type natriuretic peptide as a predictor of repeat coronary revascularization.
Sir JJ; Chung WY; Hwang SJ; Kang HJ; Cho YS; Koo BK; Chae IH; Choi DJ; Kim HS; Sohn DW; Kim CH; Oh BH; Park YB; Choi YS
Int J Cardiol; 2008 Jun; 126(3):322-32. PubMed ID: 17544525
[TBL] [Abstract][Full Text] [Related]
49. Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease.
Huang PH; Lu TM; Wu TC; Lin FY; Chen YH; Chen JW; Lin SJ
Coron Artery Dis; 2008 May; 19(3):187-93. PubMed ID: 18418236
[TBL] [Abstract][Full Text] [Related]
50. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study.
Anwaruddin S; Lloyd-Jones DM; Baggish A; Chen A; Krauser D; Tung R; Chae C; Januzzi JL
J Am Coll Cardiol; 2006 Jan; 47(1):91-7. PubMed ID: 16386670
[TBL] [Abstract][Full Text] [Related]
51. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
52. Intracranial hypertension induced by rofecoxib.
Jacob S; Rajabally YA
Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617
[TBL] [Abstract][Full Text] [Related]
53. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib.
Bagán JV; Thongprasom K; Scully C
Oral Dis; 2004 Nov; 10(6):401-3. PubMed ID: 15533219
[TBL] [Abstract][Full Text] [Related]
54. Cardiovascular risk and COX-2 inhibition in rheumatological practice.
Justice E; Carruthers DM
J Hum Hypertens; 2005 Jan; 19(1):1-5. PubMed ID: 15385947
[TBL] [Abstract][Full Text] [Related]
55. [Nonsteroidal anti-inflammatory drugs and the risk of cardiovascular diseases].
Jukić A; Kaliterna DM; Radić M
Reumatizam; 2010; 57(1):26-8. PubMed ID: 20941937
[TBL] [Abstract][Full Text] [Related]
56. Nephrotoxicity of selective COX-2 inhibitors.
Woywodt A; Schwarz A; Mengel M; Haller H; Zeidler H; Köhler L
J Rheumatol; 2001 Sep; 28(9):2133-5. PubMed ID: 11550988
[TBL] [Abstract][Full Text] [Related]
57. COX-2 inhibitor use after Vioxx: careful balance or end of the rope?
Fendrick AM
Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263
[No Abstract] [Full Text] [Related]
58. Life after Vioxx: the clinical implications.
Fortun PJ; Hawkey CJ
Hosp Med; 2005 May; 66(5):264-7. PubMed ID: 15920854
[No Abstract] [Full Text] [Related]
59. Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Tegeder I; Geisslinger G
Naunyn Schmiedebergs Arch Pharmacol; 2006 Apr; 373(1):1-17. PubMed ID: 16586083
[TBL] [Abstract][Full Text] [Related]
60. [New studies of COX-inhibitors, yet issues remain].
Wollheim FA
Lakartidningen; 2003 Sep; 100(38):2927-31. PubMed ID: 14558211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
